Market closed
Artiva Biotherapeutics, Inc./$ARTV
Artiva Biotherapeutics shares are trading higher after the company presented promising Phase 1/2 data for AlloNK® combined with rituximab in B-cell-Non-Hodgkin Lymphoma patients.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Ticker
$ARTV
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
96
ISIN
US04317A1079
Website
ARTV Metrics
BasicAdvanced
$44M
-
-$4.18
-
-
Price and volume
Market cap
$44M
52-week high
$6.54
52-week low
$1.78
Average daily volume
528K
Financial strength
Current ratio
13.93
Quick ratio
13.618
Long term debt to equity
6.088
Total debt to equity
8.292
Management effectiveness
Return on assets (TTM)
-33.30%
Return on equity (TTM)
-68.14%
Valuation
Price to book
0.26
Price to tangible book (TTM)
0.26
Price to free cash flow (TTM)
-0.509
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-87.00%
3-year earnings per share growth (CAGR)
-58.41%
ARTV News
AllArticlesVideos
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewsWire·2 days ago
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewsWire·1 week ago
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Artiva Biotherapeutics, Inc. stock?
Artiva Biotherapeutics, Inc. (ARTV) has a market cap of $44M as of May 16, 2025.
What is the P/E ratio for Artiva Biotherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Artiva Biotherapeutics, Inc. (ARTV) stock is 0 as of May 16, 2025.
Does Artiva Biotherapeutics, Inc. stock pay dividends?
No, Artiva Biotherapeutics, Inc. (ARTV) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Artiva Biotherapeutics, Inc. dividend payment date?
Artiva Biotherapeutics, Inc. (ARTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. (ARTV) does not currently have a Beta indicator.